Literature DB >> 17455113

Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans.

R Nakagomi-Hagihara1, D Nakai, T Tokui.   

Abstract

Coadministration of gemfibrozil (600 mg, b.i.d., 3 days) with pravastatin (40 mg/day) decreased the renal clearance of pravastatin by approximately 40% in healthy volunteers. To investigate the mechanism of this drug-drug interaction in the renal excretion process, we undertook an uptake study of pravastatin using human organic anion transporters (hOATs)-expressing S2 cells. hOAT3 and hOAT4 transported pravastatin in a saturatable manner with Michaelis--Menten constants of 27.7 microM and 257 microM respectively. On the other hand, hOAT1 and hOAT2 did not transport pravastatin. Gemfibrozil and its glucuronide and carboxylic metabolite forms inhibited the uptake of pravastatin by hOAT3 with IC(50) values of 6.8 microM, 19.7 microM and 5.4 microM, respectively. Considering the plasma concentrations of gemfibrozil and its metabolites in humans, the inhibition of hOAT3-mediated pravastatin transport by gemfibrozil and its metabolites would lead to a decrease in the renal clearance of pravastatin in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17455113     DOI: 10.1080/00498250601188808

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  17 in total

1.  Role of the efflux transporters BCRP and MRP1 in human placental bio-disposition of pravastatin.

Authors:  Marjan Afrouzian; Rabab Al-Lahham; Svetlana Patrikeeva; Meixiang Xu; Valentina Fokina; Wayne G Fischer; Sherif Z Abdel-Rahman; Maged Costantine; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  Biochem Pharmacol       Date:  2018-09-12       Impact factor: 5.858

Review 2.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 4.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

5.  Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.

Authors:  Arun K P; Venkata Subbaiah Meda; V S P Raj Kucherlapati; Anil Dubala; Deepalakshmi M; Anand VijayaKumar P R; Elango K; Suresh B
Journal:  Eur J Clin Pharmacol       Date:  2011-12-16       Impact factor: 2.953

6.  Role of Uptake Transporters OAT4, OATP2A1, and OATP1A2 in Human Placental Bio-disposition of Pravastatin.

Authors:  Valentina M Fokina; Svetlana Patrikeeva; Xiao-Ming Wang; Saki Noguchi; Masatoshi Tomi; Jörg König; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  J Pharm Sci       Date:  2021-09-28       Impact factor: 3.534

7.  Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Authors:  Koji Abe; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-12-15       Impact factor: 3.922

Review 8.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 9.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

10.  Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors.

Authors:  A Emami Riedmaier; O Burk; B A C van Eijck; E Schaeffeler; K Klein; S Fehr; S Biskup; S Müller; S Winter; U M Zanger; M Schwab; A T Nies
Journal:  Pharmacogenomics J       Date:  2015-08-04       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.